Cite
HARVARD Citation
Hageman, I. et al. (n.d.). DOP51 Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients. Journal of Crohn's and colitis. pp. i121-i122. [Online].